Rosuvastatin and cardiovascular continuum when time is important

J Am Coll Cardiol. 2010 Apr 13;55(15):1645-6; author reply 1646. doi: 10.1016/j.jacc.2009.12.031.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Fluorobenzenes / therapeutic use*
  • Follow-Up Studies
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / epidemiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Morbidity / trends
  • Multicenter Studies as Topic
  • Natriuretic Peptide, Brain / blood
  • Peptide Fragments / blood
  • Prognosis
  • Protein Precursors
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Rosuvastatin Calcium
  • Sulfonamides / therapeutic use*
  • Survival Rate / trends
  • Time Factors
  • United States / epidemiology

Substances

  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Peptide Fragments
  • Protein Precursors
  • Pyrimidines
  • Sulfonamides
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Rosuvastatin Calcium